Home Serum uric acid levels and risk of prehypertension: a meta-analysis
Article
Licensed
Unlicensed Requires Authentication

Serum uric acid levels and risk of prehypertension: a meta-analysis

  • Menglin Jiang , Dandan Gong and Yu Fan EMAIL logo
Published/Copyright: June 25, 2016
Become an author with De Gruyter Brill
Submit Manuscript Author Information
Clinical Chemistry and Laboratory Medicine (CCLM)
From the journal Clinical Chemistry and Laboratory Medicine (CCLM) Volume 55 Issue 3

Abstract

Elevated serum uric acid (SUA) levels may increase the risk of prehypertension. However, the findings from these studies remain conflicting. The objective of this study was to determine the relationship between SUA levels and risk of prehypertension by conducting a meta-analysis. We conducted a comprehensive literature search of PubMed, Embase, China National Knowledge Infrastructure, VIP, and the Wangfang database without language restrictions through May 2015. Observational studies assessing the relationship between SUA levels and prevalence of prehypertension were included. Pooled adjust odds ratio (OR) and corresponding 95% confidence intervals (CI) of prehypertension were calculated for the highest vs. lowest SUA levels. Prehypertension was defined as systolic blood pressure (BP) ranging from 120 to 139 mmHg or diastolic BP ranging from 80 to 89 mmHg. Eight cross-sectional studies with a total of 21,832 prehypertensive individuals were included. Meta-analysis showed that elevated SUA levels were associated with increased risk of prehypertension (OR: 1.84; 95% CI: 1.42–2.38) comparing the highest vs. lowest level of SUA levels. Subgroup analyses showed that elevated SUA levels significantly increased the risk of prehypertension among men (OR: 1.60; 95% CI: 1.12–2.21) and women (OR: 1.59; 95% CI: 1.17–2.16). Elevated SUA levels are positively associated with the risk of prehypertension in the general population. However, more well-designed longitudinal studies are needed before a definitive conclusion can be drawn due to the cross-sectional studies included are susceptible to bias.

Keywords: meta-analysis; prehypertension; serum uric acid
Corresponding author: Prof. Yu Fan, Institute of Molecular Biology and Translational Medicine, The Affiliated People’s Hospital, Jiangsu University, No. 8 Dianli Road, Zhenjiang 212002, Jiangsu, P.R. China, Phone: +86-511-88915233, Fax: +86-511-85234387

  1. Author contributions: All the authors have accepted responsibility for the entire content of this submitted manuscript and approved submission.

  2. Research funding: This work was supported by Jiangsu Provincial Key&D Special Fund (BE2015666).

  3. Employment or leadership: None declared.

  4. Honorarium: None declared.

  5. Competing interests: The funding organization(s) played no role in the study design; in the collection, analysis, and interpretation of data; in the writing of the report; or in the decision to submit the report for publication.

References

1. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL, Jr., et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. J Am Med Assoc 2003;289:2560–72.10.1001/jama.289.19.2560Search in Google Scholar PubMed

2. Jin N, Li G, Li H, Chen L, Leng B. Incidence and risk factors of prehypertension among adults in mainland China: a meta-analysis. Nan Fang Yi Ke Da Xue Xue Bao 2013;33:1738–43.Search in Google Scholar

3. Zheng L, Sun Z, Zhang X, Xu C, Li J, Hu D, et al. Predictors of progression from prehypertension to hypertension among rural Chinese adults: results from Liaoning Province. Eur J Cardiovasc Prev Rehabil 2010;17:217–22.10.1097/HJR.0b013e328334f417Search in Google Scholar PubMed

4. Guo X, Zou L, Zhang X, Li J, Zheng L, Sun Z, et al. Prehypertension: a meta-analysis of the epidemiology, risk factors, and predictors of progression. Tex Heart Inst J 2011;38:643–52.Search in Google Scholar

5. Grayson PC, Kim SY, LaValley M, Choi HK. Hyperuricemia and incident hypertension: a systematic review and meta-analysis. Arthritis Care Res (Hoboken) 2011;63:102–10.10.1002/acr.20344Search in Google Scholar PubMed PubMed Central

6. Feig DI, Johnson RJ. Hyperuricemia in childhood primary hypertension. Hypertension 2003;42:247–52.10.1161/01.HYP.0000085858.66548.59Search in Google Scholar PubMed PubMed Central

7. Liang J, Xue Y, Zou C, Zhang T, Song H, Qi L. Serum uric acid and prehypertension among Chinese adults. J Hypertens 2009;27:1761–5.10.1097/HJH.0b013e32832e0b44Search in Google Scholar PubMed

8. Wang YY, Li GP, Wei J, Li LF, Song SY, Jia H. Relationship between serum uric acid and hyperfension and pre-hypertension. Shandong Med J 2012;52:35–7.Search in Google Scholar

9. Peng H, Ding J, Peng Y, Zhang Q, Xu Y, Chao X, et al. Hyperuricemia and microalbuminuria are separately and independently associated with prehypertension among Chinese Han women. Metab Syndr Relat Disord 2012;10:202–8.10.1089/met.2011.0119Search in Google Scholar PubMed

10. Bao X, Wang Q, Chen G, Liang R, Zhang S. Serum concentration of uric acid associated with prehypertension among Chinese population. Angiology 2014;65:800–5.10.1177/0003319713507628Search in Google Scholar PubMed

11. Wang HY. Clinical significance of detection of serum uric acid in hypertension and pre-hypertension. China Med Pharm 2014;4:124–5.Search in Google Scholar

12. Jiang L, Mo D, Yang R, Ye Q, Wu J, Yu G, et al. Joint effects of serum uric acid and body mass index on risk of prehypertension in Chinese population. Clin Chim Acta 2015;446:1–5.10.1016/j.cca.2015.03.040Search in Google Scholar PubMed

13. Syamala S, Li J, Shankar A. Association between serum uric acid and prehypertension among US adults. J Hypertens 2007;25:1583–9.10.1097/HJH.0b013e32813aeb6cSearch in Google Scholar PubMed

14. Lotufo PA, Baena CP, Santos IS, Bensenor IM. Serum uric acid and prehypertension among adults free of cardiovascular diseases and diabetes: baseline of the Brazilian longitudinal study of adult health (ELSA-Brasil). Angiology 2016;67:180–6.10.1177/0003319715585037Search in Google Scholar PubMed

15. Stroup DF, Berlin JA, Morton SC, Olkin I, Williamson GD, Rennie D, et al. Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis of observational studies in epidemiology (MOOSE) group. J Am Med Assoc 2000;283: 2008–12.10.1001/jama.283.15.2008Search in Google Scholar

16. von Elm E, Altman DG, Egger M, Pocock SJ, Gotzsche PC, Vandenbroucke JP. The strengthening the reporting of observational studies in epidemiology (STROBE) statement: guidelines for reporting observational studies. Ann Intern Med 2007;147:573–7.10.1097/EDE.0b013e3181577654Search in Google Scholar

17. Begg CB, Mazumdar M. Operating characteristics of a rank correlation test for publication bias. Biometrics 1994;50:1088–101.10.2307/2533446Search in Google Scholar

18. Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. Br Med J 1997;315:629–34.10.1136/bmj.315.7109.629Search in Google Scholar

19. Albrecht E, Waldenberger M, Krumsiek J, Evans AM, Jeratsch U, Breier M, et al. Metabolite profiling reveals new insights into the regulation of serum urate in humans. Metabolomics 2014;10:141–51.10.1007/s11306-013-0565-2Search in Google Scholar

20. dos Santos RL, da Silva FB, Ribeiro RF, Jr., Stefanon I. Sex hormones in the cardiovascular system. Horm Mol Biol Clin Investig 2014;18:89–103.10.1515/hmbci-2013-0048Search in Google Scholar

21. Cannoletta M, Cagnacci A. Modification of blood pressure in postmenopausal women: role of hormone replacement therapy. Int J Womens Health 2014;6:745–57.10.2147/IJWH.S61685Search in Google Scholar

22. Sumino H, Ichikawa S, Kanda T, Nakamura T, Sakamaki T. Reduction of serum uric acid by hormone replacement therapy in postmenopausal women with hyperuricaemia. Lancet 1999;354:650.10.1016/S0140-6736(99)92381-4Search in Google Scholar

23. Lipkowitz MS. Regulation of uric acid excretion by the kidney. Curr Rheumatol Rep 2012;14:179–88.10.1007/s11926-012-0240-zSearch in Google Scholar PubMed

24. Forman JP, Choi H, Curhan GC. Plasma uric acid level and risk for incident hypertension among men. J Am Soc Nephrol 2007;18:287–92.10.1681/ASN.2006080865Search in Google Scholar PubMed

25. Lu Z, Dong B, Wu H, Chen T, Zhang Y, Wu J, et al. Serum uric acid level in primary hypertension among Chinese nonagenarians/centenarians. J Hum Hypertens 2009;23:113–21.10.1038/jhh.2008.104Search in Google Scholar PubMed

26. Sarafidis PA, Nilsson PM. The metabolic syndrome: a glance at its history. J Hypertens 2006;24:621–6.10.1097/01.hjh.0000217840.26971.b6Search in Google Scholar PubMed

27. Corry DB, Eslami P, Yamamoto K, Nyby MD, Makino H, Tuck ML. Uric acid stimulates vascular smooth muscle cell proliferation and oxidative stress via the vascular renin-angiotensin system. J Hypertens 2008;26:269–75.10.1097/HJH.0b013e3282f240bfSearch in Google Scholar PubMed

28. Perlstein TS, Gumieniak O, Hopkins PN, Murphey LJ, Brown NJ, Williams GH, et al. Uric acid and the state of the intrarenal renin-angiotensin system in humans. Kidney Int 2004;66:1465–70.10.1111/j.1523-1755.2004.00909.xSearch in Google Scholar PubMed

29. Khosla UM, Zharikov S, Finch JL, Nakagawa T, Roncal C, Mu W, et al. Hyperuricemia induces endothelial dysfunction. Kidney Int 2005;67:1739–42.10.1111/j.1523-1755.2005.00273.xSearch in Google Scholar PubMed

30. Kawamoto R, Kohara K, Tabara Y, Abe M, Kusunoki T, Miki T. Insulin resistance and prevalence of prehypertension and hypertension among community-dwelling persons. J Atheroscler Thromb 2010;17:148–55.10.5551/jat.2584Search in Google Scholar PubMed

31. Soletsky B, Feig DI. Uric acid reduction rectifies prehypertension in obese adolescents. Hypertension 2012;60:1148–56.10.1161/HYPERTENSIONAHA.112.196980Search in Google Scholar PubMed

32. Yu KH, Luo SF, Tsai WP, Huang YY. Intermittent elevation of serum urate and 24-hour urinary uric acid excretion. Rheumatology (Oxford) 2004;43:1541–5.10.1093/rheumatology/keh379Search in Google Scholar PubMed

Received: 2016-4-21
Accepted: 2016-5-21
Published Online: 2016-6-25
Published in Print: 2017-3-1

©2017 Walter de Gruyter GmbH, Berlin/Boston

Articles in the same Issue

  1. Frontmatter
  2. Editorials
  3. Targeting errors in microbiology: the case of the Gram stain
  4. Time for a holistic approach and standardization education in laboratory medicine
  5. Reviews
  6. Serum uric acid levels and risk of prehypertension: a meta-analysis
  7. Lactic acidosis: an update
  8. Mini Review
  9. Progress and impact of enzyme measurement standardization
  10. Opinion Paper
  11. Critical comments to a recent EFLM recommendation for the review of reference intervals
  12. IFCC Paper
  13. Quality Indicators in Laboratory Medicine: the status of the progress of IFCC Working Group “Laboratory Errors and Patient Safety” project
  14. Genetics and Molecular Diagnostics
  15. Evaluation and comparison of three assays for molecular detection of spinal muscular atrophy
  16. General Clinical Chemistry and Laboratory Medicine
  17. Risk analysis of the preanalytical process based on quality indicators data
  18. Analytical and clinical validation of the new Abbot Architect 25(OH)D assay: fit for purpose?
  19. Looking beyond linear regression and Bland-Altman plots: a comparison of the clinical performance of 25-hydroxyvitamin D tests
  20. Next-generation osmotic gradient ektacytometry for the diagnosis of hereditary spherocytosis: interlaboratory method validation and experience
  21. Diagnosis of sphingolipidoses: a new simultaneous measurement of lysosphingolipids by LC-MS/MS
  22. Monitoring nicotine intake from e-cigarettes: measurement of parent drug and metabolites in oral fluid and plasma
  23. Development of a rapid and quantitative lateral flow assay for the simultaneous measurement of serum κ and λ immunoglobulin free light chains (FLC): inception of a new near-patient FLC screening tool
  24. A real-world evidence-based approach to laboratory reorganization using e-Valuate benchmarking data
  25. Cancer Diagnostics
  26. Utility of proGRP as a tumor marker in the medullary thyroid carcinoma
  27. Cardiovascular Diseases
  28. Can non-cholesterol sterols and lipoprotein subclasses distribution predict different patterns of cholesterol metabolism and statin therapy response?
  29. Infectious Diseases
  30. Improving Gram stain proficiency in hospital and satellite laboratories that do not have microbiology
  31. Diabetes
  32. Volumetric absorptive microsampling at home as an alternative tool for the monitoring of HbA1c in diabetes patients
  33. Corrigendum
  34. EFLM Recommendation
  35. Corrigendum to: Recommendation for the review of biological reference intervals in medical laboratories
  36. Letters to the Editor
  37. Evaluation of the trueness of serum alkaline phosphatase measurement in a group of Italian laboratories
  38. Innovative software for recording preanalytical errors in accord with the IFCC quality indicators
  39. Mixing studies for abnormal coagulation screen – the current trend
  40. Identification of 5-fluorocytosine as a new interfering compound in serum capillary zone electrophoresis
  41. How to define reference intervals to rule in healthy individuals for clinical trials?
  42. Evaluation of the performance of INDEXOR® in the archive unit of a clinical laboratory: a step to Lean laboratory
  43. Evaluation of an automated chemiluminescent immunoassay for salivary cortisol measurement. Utility in the diagnosis of Cushing’s syndrome
  44. Analysis of hemolysis, icterus and lipemia in arterial blood gas specimens
  45. Comparison of three routine insulin immunoassays: implications for assessment of insulin sensitivity and response
https://doi.org/10.1515/cclm-2016-0339
Keywords for this article
meta-analysis; prehypertension; serum uric acid

Articles in the same Issue

  1. Frontmatter
  2. Editorials
  3. Targeting errors in microbiology: the case of the Gram stain
  4. Time for a holistic approach and standardization education in laboratory medicine
  5. Reviews
  6. Serum uric acid levels and risk of prehypertension: a meta-analysis
  7. Lactic acidosis: an update
  8. Mini Review
  9. Progress and impact of enzyme measurement standardization
  10. Opinion Paper
  11. Critical comments to a recent EFLM recommendation for the review of reference intervals
  12. IFCC Paper
  13. Quality Indicators in Laboratory Medicine: the status of the progress of IFCC Working Group “Laboratory Errors and Patient Safety” project
  14. Genetics and Molecular Diagnostics
  15. Evaluation and comparison of three assays for molecular detection of spinal muscular atrophy
  16. General Clinical Chemistry and Laboratory Medicine
  17. Risk analysis of the preanalytical process based on quality indicators data
  18. Analytical and clinical validation of the new Abbot Architect 25(OH)D assay: fit for purpose?
  19. Looking beyond linear regression and Bland-Altman plots: a comparison of the clinical performance of 25-hydroxyvitamin D tests
  20. Next-generation osmotic gradient ektacytometry for the diagnosis of hereditary spherocytosis: interlaboratory method validation and experience
  21. Diagnosis of sphingolipidoses: a new simultaneous measurement of lysosphingolipids by LC-MS/MS
  22. Monitoring nicotine intake from e-cigarettes: measurement of parent drug and metabolites in oral fluid and plasma
  23. Development of a rapid and quantitative lateral flow assay for the simultaneous measurement of serum κ and λ immunoglobulin free light chains (FLC): inception of a new near-patient FLC screening tool
  24. A real-world evidence-based approach to laboratory reorganization using e-Valuate benchmarking data
  25. Cancer Diagnostics
  26. Utility of proGRP as a tumor marker in the medullary thyroid carcinoma
  27. Cardiovascular Diseases
  28. Can non-cholesterol sterols and lipoprotein subclasses distribution predict different patterns of cholesterol metabolism and statin therapy response?
  29. Infectious Diseases
  30. Improving Gram stain proficiency in hospital and satellite laboratories that do not have microbiology
  31. Diabetes
  32. Volumetric absorptive microsampling at home as an alternative tool for the monitoring of HbA1c in diabetes patients
  33. Corrigendum
  34. EFLM Recommendation
  35. Corrigendum to: Recommendation for the review of biological reference intervals in medical laboratories
  36. Letters to the Editor
  37. Evaluation of the trueness of serum alkaline phosphatase measurement in a group of Italian laboratories
  38. Innovative software for recording preanalytical errors in accord with the IFCC quality indicators
  39. Mixing studies for abnormal coagulation screen – the current trend
  40. Identification of 5-fluorocytosine as a new interfering compound in serum capillary zone electrophoresis
  41. How to define reference intervals to rule in healthy individuals for clinical trials?
  42. Evaluation of the performance of INDEXOR® in the archive unit of a clinical laboratory: a step to Lean laboratory
  43. Evaluation of an automated chemiluminescent immunoassay for salivary cortisol measurement. Utility in the diagnosis of Cushing’s syndrome
  44. Analysis of hemolysis, icterus and lipemia in arterial blood gas specimens
  45. Comparison of three routine insulin immunoassays: implications for assessment of insulin sensitivity and response
Sign up now to receive a 20% welcome discount
Institutional Access
How does access work?
Have an idea on how to improve our website?
Please write us.
© 2025 De Gruyter Brill
Downloaded on 5.11.2025 from https://www.degruyterbrill.com/document/doi/10.1515/cclm-2016-0339/html
Scroll to top button